{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:29:31Z","timestamp":1790501371740,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,6]],"date-time":"2006-01-06T00:00:00Z","timestamp":1136505600000},"content-version":"vor","delay-in-days":66,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Current regular blood transfusion programs and chelation treatment have considerably improved survival of patients with thalassemia, which resulted in a larger proportion of adult patients. However, disease\u2010 and treatment\u2010related complications in these patients progress over time, causing severe morbidity and shortened life expectancy. Stem cell transplantation still remains the only cure currently available for patients with thalassemia. This study updates transplant outcomes in 107 adult patients with median age of 22 years (range, 17\u201035 years) who received bone marrow transplantation (BMT) from human leukocyte antigen (HLA)\u2010identical related donors between 1988 and 1996 (group A) and describes the results of BMT in 15 adult patients with median age of 21 years (range, 17\u201031 years) who were treated with a new treatment protocol (Protocol 26) between 1997 and 2003 (group B). The probability of survival, event\u2010free survival, nonrejection mortality, and rejection for group A patients were 66%, 62%, 37%, and 4%, respectively, with a median follow\u2010up of 12 years (range, 8.3\u201016.2 years). Group B patients treated with the new protocol had some improvement in thalassemia\u2010free survival (67%) and lower transplant\u2010related mortality (27%) than that of previous protocols. However, transplant\u2010related mortality in these high\u2010risk patients remains elevated. Current myeloablative BMT in adult patients is characterized by higher transplant\u2010related toxicity due to an advanced phase of disease. Although this new approach to transplant adult patients with a reduced\u2010dose intensity\u2010conditioning regimen has improved thalassemia\u2010free survival, transplant\u2010related mortality in these high\u2010risk patients remains elevated.<\/jats:p>","DOI":"10.1196\/annals.1345.024","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T23:18:51Z","timestamp":1134083931000},"page":"196-205","source":"Crossref","is-referenced-by-count":82,"title":["Bone Marrow Transplantation in Adults with Thalassemia: Treatment and Long\u2010Term Follow\u2010Up"],"prefix":"10.1111","volume":"1054","author":[{"given":"JAVID","family":"GAZIEV","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PIETRO","family":"SODANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAOLA","family":"POLCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARCO","family":"ANDREANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GUIDO","family":"LUCARELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,8]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"11","article-title":"Mortality and morbidity in thalassemia with conventional treatment","volume":"19","author":"Piga A.","year":"1977","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02357-6"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3167"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002153220701"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1054\/blre.2002.0192"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04065.x"},{"key":"e_1_2_5_8_2","first-page":"57","article-title":"Marrow transplantation for thalassemia: the USA experience","volume":"19","author":"Clift R.A.","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2090"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2800"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.6.1603.1603"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.4.1164"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310903"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409013310902"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0676.1994.tb00002.x"},{"key":"e_1_2_5_16_2","first-page":"217","article-title":"Rapid determination of copper, iron, and zinc in liver biopsies","volume":"5","author":"Soriano\u2010Cubellis M.J.","year":"1984","journal-title":"Atomic Spectroscopy"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_18_2","unstructured":"Kalbfleisch J.D. & R.L. Prentice. 1980. The statistical analysis of failure time data. Wiley. New York."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92753-G"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.1.17"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700968"},{"key":"e_1_2_5_22_2","first-page":"791","article-title":"Malignant complications after BMT for thalassemia","volume":"33","author":"Gaziev J.","year":"2004","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.3.994"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","unstructured":"De Snactis V. 2002. Growth and puberty and its management in thalassemia. Horm. Res.58(suppl): 72\u201079.","DOI":"10.1159\/000064766"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1345.024","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1345.024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:53:02Z","timestamp":1695675182000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1345.024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1196\/annals.1345.024"],"URL":"https:\/\/doi.org\/10.1196\/annals.1345.024","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}